๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Gene therapy for lung cancer

โœ Scribed by Eric M. Toloza; Michael A. Morse; H. Kim Lyerly


Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
218 KB
Volume
99
Category
Article
ISSN
0730-2312

No coin nor oath required. For personal study only.

โœฆ Synopsis


Abstract

Lung cancer patients suffer a 15% overall survival despite advances in chemotherapy, radiation therapy, and surgery. This unacceptably low survival rate is due to the usual finding of advanced disease at diagnosis. However, multimodality strategies using conventional therapies only minimally improve survival rates even in early stages of lung cancer. Attempts to improve survival in advanced disease using various combinations of platinumโ€based chemotherapy have demonstrated that no regimen is superior, suggesting a therapeutic plateau and the need for novel, more specific, and less toxic therapeutic strategies. Over the past three decades, the genetic etiology of cancer has been gradually delineated, albeit not yet completely. Understanding the molecular events that occur during the multistep process of bronchogenic carcinogenesis may make these tasks more surmountable. During these same three decades, techniques have been developed which allow transfer of functional genes into mammalian cells. For example, blockade of activated tumorโ€promoting oncogenes or replacement of inactivated tumorโ€suppressing or apoptosisโ€promoting genes can be achieved by gene therapy. This article will discuss the therapeutic implications of these molecular changes associated with bronchogenic carcinomas and will then review the status of gene therapies for treatment of lung cancer. J. Cell. Biochem. ยฉ 2006 Wileyโ€Liss, Inc.


๐Ÿ“œ SIMILAR VOLUMES


Adenovirus-mediated gene therapy specifi
โœ Kazumi Nishino; Tadashi Osaki; Toru Kumagai; Takashi Kijima; Isao Tachibana; Hir ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 127 KB ๐Ÿ‘ 2 views

Recent clinical trials of gene therapy for patients with thoracic cancers have shown that these treatments were well tolerated with minimal side effects and that we need to further enhance specificity as well as efficiency of gene transfer to target cancer cells. We previously reported that mycovere

A novel high-resolution chipCE assay for
โœ Marek Minarik; Marcus Gassman; Barbora Belsanova; Milos Pesek; Jan Schouten; Ric ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 221 KB ๐Ÿ‘ 1 views

There is a growing interest in evaluating molecular markers as predictors of response to new generation of targeted cancer therapies. One of such areas is biological therapy targeting epidermal growth factor receptor gene (EGFR) in lung cancer. The testing of tumor tissue is focused on specific EGFR

Denaturing capillary electrophoresis for
โœ Lucie Benesova; Milos Pesek; Barbora Belsanova; Patrik Sekerka; Marek Minarik ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 249 KB

## Abstract The presence of activating mutations within the tyrosine kinase domain of the epidermal growth factor receptor gene has been attributed to a positive response to biological therapy of lung cancer by smallโ€molecular tyrosine kinase inhibitors, gefitinib and erlotinib. Among the two most

Gene therapy for cancer
โœ Bert O'Malley ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 34 KB
Endobronchial photodynamic therapy for l
โœ Gregory M. Loewen; Ravindra Pandey; David Bellnier; Barbara Henderson; Thomas Do ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 129 KB

## Abstract ## Background and Objective Endobronchial photodynamic therapy (PDT) is a minimally invasive technique for the palliation of major airway obstruction from lung cancer, and for the treatment of endobronchial microinvasive lung cancer. ## Study Design Results of reported clinical trial